Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the ...
This release has been updated to reflect Dr. Nicole Schrader's accurate professional background and practice details.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈